In a nutshell This study examined the addition of everolimus (Afinitor) to exemestane (Aromasin) for the treatment of patients with hormone-receptor-positive (HR+) and HER2- breast cancer. The study concluded that adding everolimus (EVE) to exemestane (EXE) did not significantly improve overall survival. Some background EXE is a treatment...
Read More
In a nutshell This study examined the effect of the drug combination, palbociclib (Ibrance) plus fulvestrant (Faslodex) on the quality of life of breast cancer patients. The study concluded that palbociclib plus fulvestrant allowed patients to maintain a good quality of life while experiencing delayed disease progression. Some background...
Read MoreIn a nutshell This study looked at risk factors associated with the prognosis of triple negative breast cancer patients who received neoadjuvant therapy. This study concluded that lymph node status after neoadjuvant therapy is the major prognostic factor for these patients. Some background Triple negative breast cancer (TNBC) is a type of cancer...
Read More
In a nutshell This study examined the effectiveness of palbociclib (Ibrance) in the treatment of hormone receptor-positive breast cancer patients. The authors found that palbociclib treatment increased progression free survival. Some background Major treatment options for hormone receptor-positive (HR+, dependent on the hormones estrogen and/or...
Read More
In a nutshell The authors aimed to determine the effectiveness and safety adding bevacizumab (Avastin) to a chemotherapy regimen in previously treated patients with metastatic (spread to other areas of the body) breast cancer. Some background Metastasis is the spread of cancer to other organs in the body. Patients with metastatic...
Read More
In a nutshell This paper examined the safety and effectiveness of carboplatin (Paraplatin) and paclitaxel (Taxol) in combination with bevacizumab (Avastin) in triple-negative breast cancer patients. Some background Triple-negative breast cancer describes cancer without the presence of the progesterone receptor, estrogen receptor and human...
Read More
In a nutshell This paper evaluated the role of progesterone receptor in determining the outcome of cancer. Some background Estrogen receptor positive and human epidermal growth factor 2 (HER2) negative breast cancer refers to cancer that has estrogen receptors present on cancer cells and HER2 absent on cancer cells. Ki-67 is a protein that...
Read More
In a nutshell This paper compared the location of triple-negative breast cancer with estrogen receptor positive breast cancer using magnetic resonance imaging (type of scan). Some background Studies have shown that the location of cancer could affect its growth. The location of cancer can also be used to predict the outcome in patients....
Read More
In a nutshell This paper reviewed triple negative breast cancer. Some background Triple-negative breast cancer refers to cancer in the absence of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2). These receptors are proteins that can be found on cells, and are often used as targets by breast...
Read More
In a nutshell This paper studied how patients with triple negative breast cancer adhere to treatment guidelines, and whether this is associated to survival rates. Some background Triple negative breast cancer refers to cancers with the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2...
Read More
In a nutshell This paper reviewed adverse events associated with treatment of breast cancer with everolimus (Afinitus). Some background Everolimus is used in postmenopausal patients for advanced breast cancer treatments. The drug has been approved for use in patients with hormone receptor positive (the presence of the estrogen...
Read MoreIn a nutshell This study investigated the potential benefit of beta blocker treatment in triple negative breast cancer patients. In this study, patients already receiving long term treatment with beta blockers before the diagnosis of cancer were investigated to examine the effect on cancer outcome. Some background Beta blockers are a class of...
Read More
